Beeline registers Phase 2/3 study of afimetoran in cutaneous lupus erythematosus
The study, led by Beeline Medicines Corporation, plans to enroll 390 participants and begin in October 2026. It evaluates afimetoran versus placebo over 24 weeks, with a total treatment period of 52 weeks, and aims to assess changes in the CLASI-A skin activity score.
Primary source
ClinicalTrials.gov registry record, October 19, 2026
Phase 2/3 Double-Blind, Placebo-Controlled Study of Afimetoran in Cutaneous Lupus Erythematosus
Read the source: Phase 2/3 Double-Blind, Placebo-Controlled Study of Afimetoran in Cutaneous Lupus Erythematosus clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation